

Research Ethics Committee Reference Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number of Patients Agreed	Maximum Number of Patients Agreed	Target Date to Recruit Patients Agreed?	Date Agreed to Recruit Target Number of Patients	Total Number of Patients Recruited at the Agreed Target Date	Date Trial Closed to Recruitment	Total Number of Study Participants Recruited	Reason for Closure of the Trial	Comments
14/EM/1005	148489	Efficacy and safety of masitinib in combination with docetaxel to placebo in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC)	Number Agreed	5	5	Date Agreed	01/07/2017	5	26/08/2016	5	Recruitment Finished	Target achieved by Trust
15/EM/0069	162273	CANC - 3694 - Obinutuzumab + GDC-0199 (ABT-199) vs Obinutuzumab + chlorambucil in CLL	Number Agreed	1	1	Date Agreed	30/06/2021	3	04/08/2016	3	Recruitment Finished	Target achieved by Trust
16/LO/0232	199168	A retrospective,international, multicentre study to describe the duration of routine treatment with abiraterone acetate in metastatic castration-resistant prostate cancer(mCRPC)patients without prior chemotherapy	Number Agreed	8	8	Date Agreed	30/10/2016	8	31/07/2016	8	Recruitment Finished	Target achieved by Trust
14/WM/1055	152229	NCRN - 3246: Masitinib/Placebo + FOLFIRI in Metastatic Colorectal Cancer	Number Agreed	5	5	Date Agreed	03/03/2017	5	25/11/2016	5	Recruitment Finished	Target achieved by Trust
14/LO/2011	159926	CCRN 2833 RE-DUAL PCI	Number Agreed	15	15	Date Agreed	26/10/2016	18	15/02/2017	18	Recruitment Finished	Target achieved by Trust
14/WM/0094	132138	CCRN 2351 (Epilepsy)	Number Agreed	1	1	Date Agreed	29/12/2017	3	24/01/2017	3	Recruitment Finished	Target achieved by Trust
15/SW/0177	180522	CANC - 4381 PREMISE	Number Agreed	3	3	Date Agreed	31/12/2016	22	31/12/2016	22	Recruitment Finished	Target achieved by Trust